Biogen Inc. Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus
- In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skin
- Following positive Phase 2 LILAC results, litifilimab is the only investigational program with consistent, positive efficacy results in multiple CLE studies; if approved litifilimab could be the first targeted therapy for this disease
- CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.